{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:00Z","timestamp":1791223860383,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jcyt.2013.02.007","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T08:50:21Z","timestamp":1364892621000},"page":"1046-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Innovation and opportunity for chimeric antigen receptor targeted T\u00a0cells"],"prefix":"10.1016","volume":"15","author":[{"given":"J. Joseph","family":"Melenhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2013.02.007_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1182\/blood-2003-01-0095","article-title":"Adoptive transfer of costimulated T\u00a0cells induces lymphocytosis in patients with relapsed\/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation","volume":"102","author":"Laport","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib3","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1182\/blood-2011-09-378398","article-title":"Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation","volume":"119","author":"Hardy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib4","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2005-08-3373","article-title":"A\u00a0phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3\/CD28 costimulation","volume":"107","author":"Porter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/14653249.2010.530649","article-title":"Tumor vaccines and beyond","volume":"13","author":"Melenhorst","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2013.02.007_bib6","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2013.02.007_bib7","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A\u00a0phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2013.02.007_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib9","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0092-8674(90)90341-B","article-title":"Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation","volume":"60","author":"Goverman","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2013.02.007_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2013.02.007_bib13","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain","volume":"178","author":"Hwu","year":"1993","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","article-title":"Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma","volume":"166","author":"Haynes","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/1074-7613(94)90086-8","article-title":"The ups and downs of T cell costimulation","volume":"1","author":"Jenkins","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2013.02.007_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1084\/jem.177.1.165","article-title":"Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7\/BB1","volume":"177","author":"Tan","year":"1993","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2013.02.007_bib19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2013.02.007_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","article-title":"The B7 and CD28 receptor families","volume":"15","author":"June","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.jcyt.2013.02.007_bib22","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/eji.1830261006","article-title":"Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors","volume":"26","author":"Alvarez-Vallina","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib23","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib24","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib25","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcyt.2013.02.007_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2013.02.007_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib28","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2013.02.007_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.6377498","article-title":"Expression of a retrovirus encoding human HPRT in mice","volume":"225","author":"Miller","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/320275a0","article-title":"Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells","volume":"320","author":"Hock","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2013.02.007_bib32","first-page":"980","article-title":"Improved retroviral vectors for gene transfer and expression","volume":"7","author":"Miller","year":"1989","journal-title":"Biotechniques"},{"key":"10.1016\/j.jcyt.2013.02.007_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib35","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in\u00a0individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20031110","article-title":"Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer","volume":"199","author":"Heemskerk","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib38","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib40","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2013.02.007_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib44","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0092-8674(81)90228-2","article-title":"Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus","volume":"25","author":"Varmus","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2013.02.007_bib47","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.6093260","article-title":"Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas","volume":"226","author":"Shen-Ong","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2013.02.007_bib49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib50","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcyt.2013.02.007_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2013.02.007_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib53","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib54","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcyt.2013.02.007_bib55","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/mt.2009.16","article-title":"Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells","volume":"17","author":"Wang","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib56","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","article-title":"Resistance of mature T cells to oncogene transformation","volume":"112","author":"Newrzela","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib58","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2013.02.007_bib59","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/mt.2010.141","article-title":"Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in\u00a0human primary T cells","volume":"18","author":"Huang","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib60","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A\u00a0foundation for universal T-cell based immunotherapy: T\u00a0cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib61","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib62","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2013.02.007_bib63","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/mt.2011.1","article-title":"CARs on track in the clinic","volume":"19","author":"Kohn","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib65","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2011-12-398719","article-title":"Good T cells for bad B cells","volume":"119","author":"Cooper","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcyt.2013.02.007_bib68","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.4049\/jimmunol.174.4.2366","article-title":"In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia","volume":"174","author":"Bonyhadi","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2013.02.007_bib69","first-page":"15","article-title":"Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody","volume":"10","author":"Mantovani","year":"1990","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.jcyt.2013.02.007_bib70","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1089\/hum.2005.16.1452","article-title":"Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression","volume":"16","author":"Lamers","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains","volume":"18","author":"Wang","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib72","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2013.02.007_bib73","first-page":"169","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jcyt.2013.02.007_bib74","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A\u00a0phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2013.02.007_bib75","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324913004088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324913004088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:17:47Z","timestamp":1761430667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324913004088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1465324913004088"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation and opportunity for chimeric antigen receptor targeted T\u00a0cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}